Difference between revisions of "Head and neck cancer - historical"
Warner-admin (talk | contribs) m (Text replacement - "#Cisplatin_.26_Fluorouracil_2|" to "#Cisplatin_.26_Fluorouracil_.28CF.29_2|") |
|||
Line 71: | Line 71: | ||
===References=== | ===References=== | ||
# Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M, Dalesio O, Kirkpatrick A, Snow GB; EORTC Head and Neck Cancer Cooperative Group. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994 Jul;5(6):521-6. [https://doi.org/10.1093/oxfordjournals.annonc.a058906 link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/7522527 PubMed] | # Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M, Dalesio O, Kirkpatrick A, Snow GB; EORTC Head and Neck Cancer Cooperative Group. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994 Jul;5(6):521-6. [https://doi.org/10.1093/oxfordjournals.annonc.a058906 link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/7522527 PubMed] | ||
+ | |||
+ | ==Cisplatin & Cetuximab {{#subobject:58744c|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | |||
+ | ===Regimen {{#subobject:c40d1f|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Years of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/jco.2005.02.4646 Burtness et al. 2005 (ECOG E5397)] | ||
+ | |1999-2001 | ||
+ | |style="background-color:#1a9851"|Phase III (E-esc) | ||
+ | |[[Head_and_neck_cancer#Cisplatin_monotherapy|Cisplatin]] | ||
+ | |style="background-color:#ffffbf"|Did not meet primary endpoint of PFS | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: Per physician discretion, patients with complete response (CR) could have treatment discontinued 2 cycles past the point at which CR was attained. Patients with partial response (PR) continued on treatment until there was evidence of CR or progression disease. Patients with stable disease (SD) could discontinue treatment after 6 cycles. Patients with progressive disease discontinued therapy.'' | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1 | ||
+ | ====Targeted therapy==== | ||
+ | *[[Cetuximab (Erbitux)]] as follows: | ||
+ | **Cycle 1: 400 mg/m<sup>2</sup> IV over 2 hours once on day 1, then 250 mg/m<sup>2</sup> IV over 60 minutes once per day on days 8, 15, 22 | ||
+ | **Cycle 2 onwards: 250 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15, 22 | ||
+ | |||
+ | '''28-day cycles (see note)''' | ||
+ | |||
+ | ===References=== | ||
+ | <!-- Presented in part at the 38th Annual Meeting of the American Society of Clinical Oncology, May 18-21, Orlando, FL, and the American Association for Cancer Research/National Cancer Institute/European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets in Cancer Therapy, November 17-21, 2003, Boston, MA. --> | ||
+ | # '''ECOG E5397:''' Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; [[Study_Groups#ECOG|ECOG]]. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005 Dec 1;23(34):8646-54. [https://doi.org/10.1200/jco.2005.02.4646 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/16314626 PubMed] NCT00003809 | ||
[[Category:Head and neck cancer regimens]] | [[Category:Head and neck cancer regimens]] |
Revision as of 20:58, 30 August 2021
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main head and neck cancer page for current regimens.
5 regimens on this page
5 variants on this page
|
Locally advanced disease, definitive therapy
Bleomycin, Methotrexate, Vinblastine/RT
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Merlano et al. 1988 | 1983-1986 | Phase III (E-switch-ic) | Bleomycin, MTX, Vinblastine, then RT | Seems to have superior PFS |
Chemotherapy
Radiotherapy
References
- Merlano M, Rosso R, Sertoli MR, Bonelli L, Margarino G, Grimaldi A, Benasso M, Gardin G, Corvó R, Scarpati D, Barbieri A, Pallestrini E, Castiglia G, Santelli A, Scasso F, Bottero G, Ciurlo E, Fracchia P, Moratti M, Santi L. Sequential versus alternating chemotherapy and radiotherapy in stage III-IV squamous cell carcinoma of the head and neck: a phase III study. J Clin Oncol. 1988 Apr;6(4):627-32. link to original article PubMed
Recurrent or metastatic disease, first-line therapy
CABO
back to top |
CABO: Cisplatin, Amithopterin (Methotrexate), Bleomycin, Oncovin (Vincristine)
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Clavel et al. 1994 | 1984-1987 | Phase III (C) | 1. CF | Seems to have superior ORR |
2. Cisplatin | Superior ORR |
Chemotherapy
References
- Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M, Dalesio O, Kirkpatrick A, Snow GB; EORTC Head and Neck Cancer Cooperative Group. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994 Jul;5(6):521-6. link to original article contains protocol PubMed
Cisplatin & Cetuximab
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Burtness et al. 2005 (ECOG E5397) | 1999-2001 | Phase III (E-esc) | Cisplatin | Did not meet primary endpoint of PFS |
Note: Per physician discretion, patients with complete response (CR) could have treatment discontinued 2 cycles past the point at which CR was attained. Patients with partial response (PR) continued on treatment until there was evidence of CR or progression disease. Patients with stable disease (SD) could discontinue treatment after 6 cycles. Patients with progressive disease discontinued therapy.
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV once on day 1
Targeted therapy
- Cetuximab (Erbitux) as follows:
- Cycle 1: 400 mg/m2 IV over 2 hours once on day 1, then 250 mg/m2 IV over 60 minutes once per day on days 8, 15, 22
- Cycle 2 onwards: 250 mg/m2 IV over 60 minutes once per day on days 1, 8, 15, 22
28-day cycles (see note)
References
- ECOG E5397: Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; ECOG. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005 Dec 1;23(34):8646-54. link to original article contains verified protocol PubMed NCT00003809